Out of 6,540 patients involved in a study, 7.1% of those with AD had mobility impairment compared to 3.9% of those without AD ...
The target action date for Rexulti in combination with sertraline to treat patients with post-traumatic stress disorder, ...
Kerenida is currently approved to slow the progression chronic kidney disease associated with type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback